Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0552W HIGH $2.66
Volume
279.91 K
Value Traded
1.05 M
Short % Float
6.42%
-1.23%Week
-34.51%1 Month
-43.29%3 Month
-29.12%6 Month
-96.58%5 Year
-94.58%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
166.62 M
EPS (TTM)
-0.58
P/E Ratio
-
Ent. Value
36.52 M
Total Shares
138.28 M
Float Shares
97.65 M
Insiders
29.38%
Institutions
62.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ALXO Catalyst Timeline
Dated clinical, regulatory and corporate events for ALX Oncology Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ALX Oncology Holdings Inc.
211Total events
12Upcoming
45Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲PublicationEvorpaceptPresentation
Nature Medicine publication of ASPEN-06 Phase 2 data for evorpacept in HER2-positive GC/GEJ cancer
HER2-positive gastric cancer or gastroesophageal junction cancersource ↗
▼Program DiscontinuationEvorpaceptCorporate
ALX Oncology elected not to pursue a U.S. registrational path with a Phase 3 trial in gastric cancer
gastric cancersource ↗
●Enrollment UpdateALX2004Trial
Enrollment continues in dose-escalation portion of Phase 1 trial of ALX2004
EGFR-expressing solid tumorssource ↗
●Management ChangeCorporate
Appointed Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
▲Debt Royalty FinancingCorporate
Refinanced existing $10 million debt with HSBC Ventures USA Inc. and secured ability to draw up to additional $20 million
◆Poster PresentationEvorpaceptPresentation
Exploratory biomarker analysis from phase 1b/2 trial of zanidatamab + evorpacept in HER2-positive mBC presented at ESMO Breast Cancer 2026
HER2-positive metastatic breast cancersource ↗
▲Oral PresentationEvorpaceptPresentation
Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026
metastatic breast cancersource ↗
◆Management ChangeCorporate
Appointment of Jeff Knight as Chief Development and Operating Officer
◆Management ChangeCorporate
Appointment of Jeff Knight as Chief Development and Operating Officer
▼Equity OfferingCorporate
Completed $150 million registered equity offering of common stock and pre-funded warrants
●Management ChangeCorporate
Barbara Klencke, M.D., appointed permanently as Chief Medical Officer
▼Equity OfferingCorporate
Pricing of underwritten offering of common stock and pre-funded warrants for gross proceeds of ~$150M
▲Biomarker DataEvorpaceptClinical Data
Exploratory analysis shows CD47 expression predictive of evorpacept response
HER2-positive breast cancersource ↗
◆Oral PresentationPresentation
Corporate presentation at 44th Annual J.P. Morgan Healthcare Conference
▲First Patient DosedEvorpaceptTrial
First patient dosed in Phase 2 ASPEN-09-Breast trial of evorpacept plus trastuzumab and chemotherapy
HER2-positive metastatic breast cancersource ↗
▲Dose Finding UpdateALX2004Trial
Third dose cohort initiated at 4mg/kg in Phase 1 trial of ALX2004
EGFR-expressing solid tumorssource ↗
◆Safety Data UpdateALX2004Clinical Data
Initial safety data expected in first half 2026
EGFR-expressing solid tumorssource ↗
▲Topline ReadoutEvorpaceptClinical Data
Topline biomarker data from exploratory analysis of evorpacept with zanidatamab in advanced HER2-positive breast cancer announced
HER2-positive breast cancersource ↗
▲Trial InitiationEvorpaceptTrial
Phase 2 ASPEN-09-Breast trial began enrollment
HER2-positive breast cancersource ↗
▲First Patient DosedALX2004Trial
Enrollment in third dose cohort at 4mg/kg began
EGFR-expressing solid tumorssource ↗
◆Safety Data UpdateEvorpaceptClinical Data
Safety and early efficacy data for ASPEN-CRC
metastatic colorectal cancersource ↗
▲Poster PresentationEvorpaceptPresentation
Poster presentation of Phase 2 IST data at ASH 2025
indolent B-cell non-Hodgkin lymphomasource ↗
▲Primary Endpoint MetEvorpaceptClinical Data
Primary endpoint of best CR rate above 80% met
indolent B-cell non-Hodgkin lymphomasource ↗
◆Poster PresentationEvorpaceptPresentation
Updated data from Phase 2 ASPEN-06 trial presented at SITC 2025
HER2-positive advanced gastric cancer and gastroesophageal junction cancersource ↗
▲Oral PresentationEvorpaceptPresentation
Data presentation at SITC from ASPEN-06 trial showing benefit in high CD47-expressing HER2-positive gastric cancer
HER2-positive gastric cancersource ↗
▲Enrollment MilestoneALX2004Trial
Enrolling second dose cohort at 2mg/kg after clearing dose 1 cohort at 1mg/kg
EGFR+ tumorssource ↗
▲Poster PresentationEvorpaceptPresentation
Poster presentation at SITC 2025 showing CD47 overexpression as predictive biomarker for evorpacept response in HER2-positive gastric cancer
gastric cancersource ↗
●Poster PresentationALX2004Presentation
Phase 1 trial design for ALX2004 presented at AACR-NCI-EORTC 2025
EGFR-expressing solid tumorssource ↗
◆Oral PresentationEvorpaceptPresentation
Updated data from ASPEN-06 trial highlighting CD47 expression as predictive biomarker to be presented at medical conference
HER2+ Gastric Cancersource ↗
▲Trial InitiationEvorpaceptTrial
Patient dosing anticipated to begin in ASPEN-Breast trial under updated protocol
HER2+ Breast Cancersource ↗
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat
▲First Patient DosedALX2004Trial
First patient dosed in Phase 1 trial of ALX2004
EGFR-expressing solid tumorssource ↗
▼Program DiscontinuationEvorpaceptCorporate
Paused ASPEN-CRC study in colorectal cancer to extend cash runway
Colorectal Cancersource ↗
▲First Patient DosedALX2004Trial
First patient dosed in Phase 1 trial of ALX2004
EGFR-expressing solid tumorssource ↗
◆Topline ReadoutEvorpaceptClinical Data
Topline results from Phase 1b I-SPY TRIAL of evorpacept with ENHERTU in breast cancer
breast cancersource ↗
◆Oral PresentationPresentation
Management to participate in Jefferies 2025 Global Healthcare Conference fireside chat
◆Trial InitiationEvorpaceptTrial
Initiation of Phase 3 registrational randomized clinical trial for evorpacept in gastric/GEJ cancer
HER2-positive gastric/gastroesophageal junction cancersource ↗
◆First Patient DosedEvorpaceptTrial
First patient dosing for ASPEN-Breast Phase 2 trial
HER2-positive metastatic breast cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How ALXO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-01 | evorpacept | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$83M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.5x
rNPV / MCap
Top 38%
Micro Cap(rank 251 of 658)
Percentile Rank
ALX Oncology Holdings Inc. carries a moderate pipeline score (40/100), with $1.1B risk-adjusted pipeline value, led by ALX2004 in NSCLC (Advanced Non-small Cell Lung Cancer) (Phase 1), across $55B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALX2004 Small moleculeNCT07085091 | NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | RECRUITING | 170 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALXO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| evorpacept | HER2-positive gastric cancer | Phase 2 | 2026-09-28 | overall ORR: 40.3%; control ORR: 26.6%; high CD47 ORR: 63.6%; control high CD47 ORR: 23.1%; median PFS: 19.5 months; control median PFS: 7.0 monthsRead More | ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lettmann JasonDirector, Officer (CHIEF EXECUTIVE OFFICER) | Sell | -2,230 294,379 held | $1.93 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALXO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.2 % (-33.3 %) | 26.93 M | 13.01 M |
ALXO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALXO ranks across every disease it competes in
Competitive Position is a premium feature
See how ALXO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALXO News
ALXO▲ +6.1%on this news
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
ALX Oncology announced the publication of ASPEN-06 Phase 2 clinical trial data in Nature Medicine, demonstrating that evorpacept combined with trastuzumab, ramucirumab, and paclitaxel achieved a 40.3% objective response rate in HER2-positive gastric cancer. The study highlights CD47 expression as a predictive biomarker for treatment efficacy. ALX is advancing its pipeline with ongoing trials, including ASPEN-09-Breast, expected to yield topline data by mid-2027.
Read more →ALXO▲ +5.1%on this news
ALX Oncology to Present at Upcoming Investor Conferences in September
ALX Oncology will participate in three investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, Cantor Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The leadership will engage in fireside chats and one-on-one meetings to discuss their innovative cancer therapies and ongoing clinical trials.
Read more →ALXO▲ +9.9%on this news
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology reported its Q2 2026 financial results and provided updates on its clinical trials. The company is on track for a mid-2027 topline data readout from its Phase 2 ASPEN-09-Breast trial. Positive data from a Phase 1b/2 trial was presented at ESMO Breast Cancer 2026, and enrollment in the Phase 1 trial of ALX2004 is progressing well. The company also strengthened its leadership team and financial position.
Read more →ALXOALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology has granted an inducement stock option to Michael Listgarten, its new General Counsel, to purchase 500,000 shares at $2.20 each. This option is part of the company's 2025 Inducement Equity Incentive Plan and vests over time. ALX Oncology continues to develop innovative therapies, including its lead candidate, evorpacept.
Read more →ALXO▼ -5.9%on this news
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
ALX Oncology has appointed Scott Garland as the new Chairman of the Board, succeeding co-founder Corey Goodman. Garland, who has been a board member since November 2022, is expected to guide the company through its next growth phase. Additionally, Michael Listgarten has been appointed as General Counsel, bringing over 30 years of legal experience in the biopharmaceutical sector.
Read more →ALXO▼ -5.3%on this news· ran to -18% by day 3
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
ALX Oncology will present at the 2026 Jefferies Global Healthcare Conference in New York. The presentation, scheduled for June 3, 2026, will feature a fireside chat format. ALX Oncology is known for its innovative cancer therapies, including evorpacept and ALX2004, which are currently in clinical trials.
Read more →ALXO▲ +11.2%on this news
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology reported its Q1 2026 financial results, highlighting promising data from the Phase 1b/2 trial of evorpacept combined with zanidatamab for HER2-positive breast cancer. The company is optimistic about the ongoing ASPEN-09-Breast trial and the ALX2004 Phase 1 trial. Additionally, ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer to enhance its operational capabilities.
Read more →ALXO▼ -10.5%on this newsshared move
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
Read more →ALXO▲ +7.6%on this news· ran to +22% by day 3
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
ALX Oncology announced that data from its Phase 1b/2 trial of evorpacept in combination with zanidatamab for HER2-positive metastatic breast cancer will be presented at the ESMO Breast Cancer 2026 Congress. The presentation will focus on biomarker analyses that suggest CD47 expression may predict treatment response. The company will also report its Q1 2026 financial results shortly after the presentation.
Read more →ALXO▼ -7.7%on this newsshared move
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
ALX Oncology has appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Knight, a veteran in the biopharmaceutical sector, brings over three decades of experience in clinical development and operations. His leadership is expected to enhance ALX's capabilities as the company progresses with its clinical programs, including evorpacept and ALX2004.
Read more →ALXO▼ -10.2%on this news
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALX Oncology reported its financial results for Q4 and full year 2025, highlighting strong progress in clinical development for its therapies, evorpacept and ALX2004. The company anticipates multiple data sets and milestones in the next 12 to 18 months, supported by a successful $150 million equity offering. Evorpacept shows promise as a predictive biomarker in HER2-positive cancers, while ALX2004 continues to enroll patients in its Phase 1 trial.
Read more →ALXO▲ +12.1%on this news
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
ALX Oncology will participate in several investor conferences in Q1 2026, including the Wells Fargo Executive Biotech Summit and the TD Cowen Annual Health Care Conference. The company aims to showcase its innovative cancer therapies, particularly its lead candidate, evorpacept, which is undergoing various clinical trials. These events provide a platform for ALX Oncology to connect with investors and discuss its advancements in cancer treatment.
Read more →ALXO▲ +12.1%on this news
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
ALX Oncology Holdings Inc. will report its fourth quarter and full year 2025 financial results on February 27, 2026. The company will also provide a business update during a teleconference. ALX Oncology is focused on developing novel therapies for cancer treatment, with ongoing clinical trials for its lead candidate, evorpacept.
Read more →ALXO▲ +10.8%on this news· ran to +28% by day 3
ALX Oncology Announces Pricing of Underwritten Offering
ALX Oncology has announced the pricing of an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $150 million. The offering includes 76,979,112 shares of common stock priced at $1.57 each. The funds will be used to support the clinical development of their lead candidate, evorpacept, and for general corporate purposes. The offering is expected to close on February 2, 2026, pending customary conditions.
Read more →ALXO▲ +10.8%on this news· ran to +28% by day 3shared move
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
ALX Oncology has released new data from a Phase 1b/2 trial indicating that CD47 expression levels can predict the response to evorpacept combined with zanidatamab in HER2-positive metastatic breast cancer patients. The findings support a biomarker-driven approach for optimizing patient selection. The full analysis has been submitted for presentation at an upcoming scientific conference.
Read more →ALXO▲ +8.9%on this news
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
ALX Oncology has initiated the Phase 2 ASPEN-09-Breast trial for evorpacept, targeting HER2-positive metastatic breast cancer. The trial combines evorpacept with trastuzumab and chemotherapy, with interim results expected in Q3 2026. Additionally, the Phase 1 trial for ALX2004 has begun enrolling patients in a third dose cohort, aiming to provide initial safety data in 1H 2026.
Read more →ALXO▲ +8.9%on this news
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALX Oncology will participate in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Jason Lettmann and CMO Barbara Klencke will present on January 15, 2026. The company is focused on developing novel cancer therapies, including its lead candidate, evorpacept, which is in multiple clinical trials. ALX2004, another pipeline candidate, is currently in a Phase 1 trial for solid tumors.
Read more →ALXOALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
ALX Oncology announced positive results from a Phase 2 trial of evorpacept combined with rituximab and lenalidomide for patients with indolent B-cell non-Hodgkin lymphoma. The trial reported a 92% complete response rate, significantly higher than the historical 50% for the standard treatment alone. The combination therapy was well-tolerated and demonstrated strong anti-tumor activity, with further evaluations planned for minimal residual disease.
Read more →About ALX Oncology Holdings Inc.
Headquarters323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next ALXO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime